Biotechnology News and Research RSS Feed - Biotechnology News and Research

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]
Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information. [More]
MSU researchers show how bacterial immune systems fight off viruses

MSU researchers show how bacterial immune systems fight off viruses

When this week's print issue of the journal Science comes out, a collective cheer will go up from New Mexico, Montana and even the Netherlands, thanks to the type of collaborative effort that is more and more the norm in these connected times. Yes, the research was brilliant, and if we're lucky, it will produce innovations in biology, medicine, biotechnology and agriculture. It could save lives, and it happened because this scientist talked with that one, that one knew another one, and brilliant minds overcame geographic distance to advance human understanding. [More]
Researchers find new method to measure modified protein structures in biological sample

Researchers find new method to measure modified protein structures in biological sample

Cells regulate protein functions in a wide variety of ways, including by modifying the protein structure. In an instant, a protein can take on another form and perform no or even the "wrong" function: in humans, proteins that fold wrongly can cause serious diseases such as Alzheimer's, Parkinson's or cystic fibrosis. [More]
Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen announces phase 3 ivabradine data for treatment of chronic HF

Amgen (NASDAQ: AMGN) today announced data from the Phase 3 SHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) study evaluating ivabradine in patients with chronic heart failure (HF) were presented at the 18th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) in Las Vegas. [More]
Scientists measure responses to rewards during nicotine withdrawal across species

Scientists measure responses to rewards during nicotine withdrawal across species

Cigarette smoking is a leading cause of preventable death worldwide and is associated with approximately 440,000 deaths in the United States each year, according to the U.S. Centers for Disease Control and Prevention, but nearly 20 percent of the U.S. population continues to smoke cigarettes. [More]
Global study shows accuracy of RNA genomic sequencing techniques

Global study shows accuracy of RNA genomic sequencing techniques

Physicians envision a future in which genomic data from patients is heavily used to manage care - but experts have questioned the accuracy and reliability of these analyses. Now, a study by 150 researchers in 12 countries finds real strength and agreement across RNA genomic sequencing techniques and laboratories - as well as ways to improve what little variability exists to set a new high standard. [More]
Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough. [More]
NSF, NIH, USDA receive more than $12 million in new EEID grants

NSF, NIH, USDA receive more than $12 million in new EEID grants

Ebola, MERS (Middle East Respiratory Syndrome), malaria, antibiotic-resistant infections: Is our interaction with the environment somehow responsible for their increased incidence? [More]
Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

Cancer Research UK, CRT partner with Asterias to trail novel immunotherapy treatment for lung cancer

CANCER RESEARCH UK and Cancer Research Technology , the charity's development and commercialisation arm, have reached an agreement with Asterias Biotherapeutics, Inc., a biotechnology company in the emerging field of regenerative medicine, to take forward Asterias' novel immunotherapy treatment AST-VAC2 into clinical trials in subjects with non-small cell lung cancer. [More]
New book brings awareness to debate surrounding stem cell research

New book brings awareness to debate surrounding stem cell research

Mary Ann Liebert, Inc., leading publisher of over 80 science, technology, and medical publications, announced today the launch of first time hard cover title Inevitable Collision: The Inspiring Story that Brought Stem Cell Research to Conservative America, in an effort to bring awareness to the growing conversation and debate surrounding stem cell research and regenerative medicine. [More]
Clinical trial of stem cell-derived therapy for patients with Type 1 diabetes

Clinical trial of stem cell-derived therapy for patients with Type 1 diabetes

Researchers at the University of California, San Diego School of Medicine, in partnership with ViaCyte, Inc., a San Diego-based biotechnology firm specializing in regenerative medicine, have launched the first-ever human Phase I/II clinical trial of a stem cell-derived therapy for patients with Type 1 diabetes. [More]
National health research forum

National health research forum

Leaders from government, industry, academia and patient advocacy organizations will explore the future of R&D investments, policy trends, public-private partnerships, public health and social sciences research, global health threats and other timely medical and health research issues in panel discussions hosted by Research!America. [More]
Experimental vaccine protects monkeys exposed to Ebola virus

Experimental vaccine protects monkeys exposed to Ebola virus

One shot of an experimental vaccine made from two Ebola virus gene segments incorporated into a chimpanzee cold virus vector (called chimp adenovirus type 3 or ChAd3) protected all four macaque monkeys exposed to high levels of Ebola virus 5 weeks after inoculation, report National Institutes of Health (NIH) scientists and their collaborators. [More]
Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix acquires novel orphan drug candidate for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin). [More]
PHI collaborates with Northeastern University for establishing novel cell analysis applications

PHI collaborates with Northeastern University for establishing novel cell analysis applications

Phase Holographic Imaging (PHI) today announces a collaboration agreement with Northeastern University of Boston. [More]
Prana's PBT2 receives FDA Orphan Drug designation for treatment of Huntington disease

Prana's PBT2 receives FDA Orphan Drug designation for treatment of Huntington disease

Prana Biotechnology has today announced the US Food and Drug Administration has granted Orphan Drug designation to PBT2 for the treatment of Huntington Disease. [More]
University of Leicester researchers uncover new insights into day-length measurement in flies

University of Leicester researchers uncover new insights into day-length measurement in flies

Researchers from the University of Leicester have for the first time provided experimental evidence for a genetic link between two major timing mechanisms, the circadian clock and the seasonal timer. [More]
Oncolytics Biotech completes randomized Phase 2 study of ovarian, fallopian tube cancer

Oncolytics Biotech completes randomized Phase 2 study of ovarian, fallopian tube cancer

Oncolytics Biotech Inc. today announced that patient enrollment has been completed in a randomized Phase 2 study of paclitaxel plus REOLYSIN® versus paclitaxel alone in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H). [More]
Researchers examine impact of continuous increases in health care costs

Researchers examine impact of continuous increases in health care costs

If continuing increases in health care costs are inevitable, as some economists predict, is it possible for health care delivery reform to succeed in reducing the overall burden of health care expenditures on the U.S. economy? According to the results of a new study, the focus should shift from cost control to improving utilization rates and quality outcomes, as described in detail in an article in Population Health Management, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]